Skip to content

Bruce M Cohen

3 papers in the library · 267 citations · publishing 2010-2012

Papers

Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.

Biological psychiatry November 15, 2012 Mohini Ranganathan, Ashley Schnakenberg, Patrick D Skosnik et al. 125 citations

Inhaled salvinorin A, the active ingredient in Salvia divinorum, produces transient psychotomimetic and perceptual alterations including dissociative and somaesthetic effects, increases plasma cortisol and prolactin, and reduces resting electroencephalogram spectral power. It does not cause euphoria, cognitive deficits, or changes in vital signs, and the effects are not dose-related. The substance is very well-tolerated without acute or delayed adverse effects, and its lack of euphoric effects suggests a low addictive potential similar to other hallucinogens.

Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats.

Psychopharmacology June 1, 2010 Christina L Nemeth, Tracie A Paine, Joseph E Rittiner et al. 102 citations

Two drugs that alter perception and cognition in humans—salvinorin A (a kappa-opioid receptor agonist) and ketamine (an NMDA receptor antagonist)—produced similar disruptions in attention and motivation in rats tested on a food-motivated attention task. Both drugs increased omission errors (signs of reduced motivation) and slowed correct response latencies (processing deficits). Pre-feeding before testing produced a subtly different pattern, suggesting the drug effects were not purely motivational. A kappa-opioid receptor blocker (JDTic) prevented all effects of salvinorin A and some effects of ketamine. Binding studies showed ketamine also activates kappa-opioid receptors, though less potently than salvinorin A. These findings suggest kappa-opioid receptors may contribute to cognitive disruptions seen in conditions like schizophrenia.

Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial.

Psychopharmacology April 1, 2011 John E Mendelson, Jeremy R Coyle, Juan Carlos Lopez et al. 40 citations

Salvinorin A (SA), the psychoactive compound in the hallucinogenic plant Salvia divinorum, was administered sublingually at doses up to 4 mg to eight experienced users in a placebo-controlled ascending-dose study. No dose produced significantly greater physiological or subjective effects than placebo, and the effects did not resemble those of smoked Salvia divinorum. SA was detectable in plasma and urine but mostly below the reliable quantification limit of 0.5 ng/mL. The results suggest that sublingual bioavailability of SA is low, indicating that higher doses, alternate formulations, or other routes of administration are needed to study its effects in humans.